S100P
Placental S100 (S100P) binding protein was originally identified in placenta and subsequently is associated with cancer. S100P is a member of S100 family of proteins, which function as extracellular and/or intracellular regulators of diverse cellular processes and participate in various human pathologies. Functional studies of S100P indicate that its biological activities are exerted through extracellular signaling via RAGE receptor, resulting in increased proliferation and survival, or through intracellular interaction with ezrin, leading to increased cell migration and metastasis. S100P expression has been detected in human tumor cell lines and tissues derived from breast, prostate, pancreas, lung and colon, where it was associated with a malignant phenotype, hormone independence and resistance to chemotherapy. Over-expression of S100P was shown to promote tumorigenesis and metastasis in diverse cancer models. Recent studies have shown that S100P is highly expressed in bladder cancers (poorly differentiated), where expression is localized in the cytoplasm and in the nucleus of cell. S100P has been shown to be negative in the vast majority of renal cell and prostate carcinomas; thus S100P can be used in the differential diagnosis of bladder, prostate and renal cell carcinomas. Additionally, S100P was useful in the diagnosis of adenocarcinoma of the pancreas in fine-needle aspiration biopsy specimens.
| Ordering Information |
Catalog Number |
Volume |
| Concentrate |
ACI 3010 |
A, B |
| Predilute |
API 3010 |
AA |
| intelliPATH™ |
N/A |
N/A |
| VP Echelon |
N/A |
N/A |
| A / AK = 0.1 ml |
B / BK = 0.5 ml |
C / CK = 1.0 ml |
G5 = 5.0 ml |
AA = 6.0 ml |
H / G25 = 25 ml |
L = 100 ml |
